Jump to content

Developing Countries Vaccine Manufacturers Network

Add links
From Wikipedia, the free encyclopedia
DCVMN International
(Developing Countries Vaccine Manufacturers Network)
Formation2000; 25 years ago
Legal statusNon-profit organization
PurposeVaccine equity
HeadquartersNyon, Switzerland
CEO
Rajinder Suri
Websitehttps://dcvmn.org/

The Developing Countries Vaccine Manufacturers Network (DCVMN International) is a voluntary non-partisan public health alliance of health organizations and vaccine manufacturers. DCVMN aims to protect people globally against known and emerging infectious diseases through the provision of a consistent supply of high quality vaccines at affordable prices for developing countries, to achieve vaccine equity.[1][2][3] DCVMN includes many It was established in 2000[4]/2001,[5] and is headquartered in Switzerland.[4]

As of 2025, DCVMN International comprises over 48 public and private manufacturers across 17 countries and territories in Africa, Asia, Europe, the Middle East, and Latin America. During the COVID-19 Pandemic, DCVMN members supplied more than 60% of the global vaccine supply of COVID-19 vacccines, with 8 different vaccine technology platforms used to develop these vaccines between all of the 20 members that are engaging in the COVID-19 vaccine effort. DCVMN members reported that they had the capability to supply over 400 distinct vaccine products to 170 countries, more than 100 of these vaccines have WHO Prequalification, totalling more than 6 billion vaccine doses annually.[6]

Members are developing and producing novel vaccines for illnesses including neglected tropical diseases:[7] rotavirus, Japanese encephalitis, pertussis,[8] haemophilus influenzae, hepatitis B,[9] hepatitis E, meningitis A,[3] cholera, poliovirus, human papillomavirus infection, dengue fever, Chikungunya virus and COVID-19.[6][10]

The DCVMN is active in identifying obstacles in the processes of vaccine registration and use. It works to increase coordination of requirements and procedures to improve the prequalification, procurement and supply of vaccines. This can involve governments in different countries, the World Health Organization (WHO), and United Nations agencies such as UNICEF.[11][12][13]

The Developing Countries Vaccine Manufacturers Network has received funding from the Bill & Melinda Gates Foundation.[4]

DCVMN International is registered as a legal entity under Swiss jurisdiction, operating under Articles 60 and beyond of the Swiss Civil Code. While the DCVMN headquarters are anchored in Switzerland, the CEO's office is based in India.

References

[edit]
  1. ^ "DCVMN". Developing Countries Vaccine Manufacturers Network. Retrieved 26 April 2022.
  2. ^ Poeloengan, Thamrin; Raw, Isaias; Martinez, Luis Herrera; El-Abbadi, Mohamed (12 November 2001). "Developing Country Vaccine Manufacturers Network (DCVMN), 26–27 April 2001, Bandung, Indonesia". Vaccine. 20 (3): 285–287. doi:10.1016/S0264-410X(01)00333-4. ISSN 0264-410X. PMID 11672886. Retrieved 26 April 2022.
  3. ^ a b Pagliusi, Sonia; Makhoana, Morena; Datla, Mahima; Leite, Luciana; Hendriks, Jan; Gholami, Alireza; Huang, Weidan; Gao, Yongzhong; Jadhav, Suresh; Harshavardhan, Gutla V. J. A.; Wu, Yonglin; Suhardono, Mahendra; Homma, Akira (28 June 2013). "Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012". Vaccine. 31 (31): 3111–3115. doi:10.1016/j.vaccine.2013.04.082. ISSN 1873-2518. PMID 23684836. Retrieved 26 April 2022.
  4. ^ a b c "Developing Countries Vaccine Manufactures Network (DCVMN) International". Devex. Retrieved 26 April 2022.
  5. ^ Hendriks, Jan; Blume, Stuart (7 July 2016). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi:10.1186/s12992-016-0176-6. ISSN 1744-8603. PMC 4936226. PMID 27388678.
  6. ^ a b Hayman, Benoit; Dennehy, Maureen (23 August 2021). "Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization". Vaccine. 39 (36): 5153–5161. doi:10.1016/j.vaccine.2021.07.044. ISSN 1873-2518. PMC 8330991. PMID 34362602.
  7. ^ Jadhav, S.; Gautam, M.; Gairola, S. (May 2014). "Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices". Clinical Microbiology and Infection. 20: 37–44. doi:10.1111/1469-0691.12568. PMID 24476201. Retrieved 26 April 2022.
  8. ^ Pagliusi, Sonia; Leite, Luciana C.C.; Datla, Mahima; Makhoana, Morena; Gao, Yongzhong; Suhardono, Mahendra; Jadhav, Suresh; Harshavardhan, Gutla V.J.A.; Homma, Akira (April 2013). "Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all" (PDF). Vaccine. 31: B176 – B183. doi:10.1016/j.vaccine.2012.11.060. PMID 23598479. Retrieved 27 April 2022.
  9. ^ Jadhav, Suresh; Datla, Mahima; Kreeftenberg, Hans; Hendriks, Jan (20 March 2008). "The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries". Vaccine. 26 (13): 1611–1615. doi:10.1016/j.vaccine.2008.01.034. ISSN 0264-410X. PMID 18294742. Retrieved 26 April 2022.
  10. ^ Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D.; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand; Evtushenko, Anatoly; Jadhav, Suresh; Meng, Weining; Dat, Do Tuan; Huang, Weidan; Desai, Samir (22 July 2020). "Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply". Vaccine. 38 (34): 5418–5423. doi:10.1016/j.vaccine.2020.06.022. ISSN 0264-410X. PMC 7287474. PMID 32600908.
  11. ^ Dellepiane, Nora; Pagliusi, Sonia (21 May 2019). "Opportunities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective". Vaccine. 37 (23): 2982–2989. doi:10.1016/j.vaccine.2019.03.025. ISSN 0264-410X. PMID 31027928. S2CID 135439603.
  12. ^ Dellepiane, Nora; Pagliusi, Sonia (7 June 2018). "Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes". Vaccine. 36 (24): 3389–3396. doi:10.1016/j.vaccine.2018.03.049. ISSN 0264-410X. PMC 6278877. PMID 29724510.
  13. ^ Hayman, Benoit; Bowles, Alex; Evans, Beth; Eyermann, Elizabeth; Nepomnyashchiy, Lyudmila; Pagliusi, Sonia (22 February 2021). "Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities". Vaccine. 39 (8): 1190–1194. doi:10.1016/j.vaccine.2020.12.085. ISSN 0264-410X. PMC 7909323. PMID 33487466. Retrieved 26 April 2022.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Developing_Countries_Vaccine_Manufacturers_Network&oldid=1300365561"